ReviewWorld journal of gastrointestinal oncology2014
Use of blood-based biomarkers for early diagnosis and surveillance of colorectal cancer.
Review in World journal of gastrointestinal oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02364154 (Metabolic Phenotyping of Blood Plasma by Means of 1H-NMR Spectroscopy), which is not on this map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Metabolic Phenotyping of Blood Plasma by Means of 1H-NMR Spectroscopy: a New Tool to Detect Colorectal Cancer?
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic Assessment of septin9 DNA Methylation for Colorectal Cancer Using Blood Detection: A Meta-Analysis.Pathology oncology research : POR · 2019Pooled it
- Article
- Sample preparation and cleanup methods for clinical top-down proteomics.Expert review of proteomics · 2025Review
- Characteristics of a cost-effective blood test for colorectal cancer screening.Journal of the National Cancer Institute · 2024Article
- Proteomics: Unraveling the Cross Talk Between Innate Immunity and Disease Pathophysiology, Diagnostics, and Treatment Options.Advances in experimental medicine and biology · 2024Review
- Circulating Nucleic Acids in Colorectal Cancer: Diagnostic and Prognostic Value.Disease markers · 2024Review
- MEvA-X: a hybrid multiobjective evolutionary tool using an XGBoost classifier for biomarkers discovery on biomedical datasets.Bioinformatics (Oxford, England) · 2023Article
- miR-3133 is an unfavorable prognosis factor and tumor suppressor in colon cancer.Functional & integrative genomics · 2023Article
- Multi-Omics Approaches in Colorectal Cancer Screening and Diagnosis, Recent Updates and Future Perspectives.Cancers · 2022Review
- Analysis of blood markers for early colorectal cancer diagnosis.Journal of gastrointestinal oncology · 2022Article
- Long noncoding RNAs as promising biomarkers in cancer.Non-coding RNA research · 2022Review
- 1H-NMR Based Metabolomics Technology Identifies Potential Serum Biomarkers of Colorectal Cancer Lung Metastasis in a Mouse Model.Cancer management and research · 2022Article
- Clinical significance of golgi protein-73 as a diagnostic marker for Egyptian patients with colorectal cancer: Preliminary study.Cancer reports (Hoboken, N.J.) · 2021Article
- Electrochemical biosensors for measurement of colorectal cancer biomarkers.Analytical and bioanalytical chemistry · 2021Review
- The Roadmap of Colorectal Cancer Screening.Cancers · 2021Review
- Comparison of Proteomic Technologies for Blood-Based Detection of Colorectal Cancer.International journal of molecular sciences · 2021Article
- Contribution of Epithelial and Gut Microbiome Inflammatory Biomarkers to the Improvement of Colorectal Cancer Patients' Stratification.Frontiers in oncology · 2021Review
- Blood-derived molecular signatures as biomarker panels for the early detection of colorectal cancer.Molecular biology reports · 2020Review
- Colorectal cancer screening: Assessment ofJournal of advanced research · 2020Article
- Clinical value evaluation of serum markers for early diagnosis of colorectal cancer.World journal of gastrointestinal oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early screening for colorectal cancer (CRC) holds the key to combat and control the increasing global burden of CRC morbidity and mortality. However, the current available screening modalities are severely inadequate because of their high cost and cumbersome preparatory procedures that ultimately lead to a low participation rate. People simply do not like to have colonoscopies. It would be ideal, therefore, to develop an alternative modality based on blood biomarkers as the first line screening test. This will allow for the differentiation of the general population from high risk individuals. Colonoscopy would then become the secondary test, to further screen the high risk segment of the population. This will encourage participation and therefore help to reach the goal of early detection and thereby reduce the anticipated increasing global CRC incidence rate. A blood-based screening test is an appealing alternative as it is non-invasive and poses minimal risk to patients. It is easy to perform, can be repeated at shorter intervals, and therefore would likely lead to a much higher participation rate. This review surveys various blood-based test strategies currently under investigation, discusses the potency of what is available, and assesses how new technology may contribute to future test design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.